Amicus Therapeutics, Inc.(FOLD)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Insider Transactions
Open-market activity and option exercises
78 insider transactions found. Showing 10 of 78 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| CAMPBELL BRADLEY LEWIS | Chief Executive Officer | 75,000 | $1073182.00 | Jan 20, 2026 |
| CAMPBELL BRADLEY LEWIS | Chief Executive Officer | 75,000 | $457500.00 | Jan 20, 2026 |
| CLARK DAVID MICHAEL | Officer | 25,642 | $363380.00 | Dec 19, 2025 |
| CAMPBELL BRADLEY LEWIS | Chief Executive Officer | 77,926 | $846011.00 | Dec 15, 2025 |
| CAMPBELL BRADLEY LEWIS | Chief Executive Officer | 70,426 | $635947.00 | Dec 15, 2025 |
| CLARK DAVID MICHAEL | Officer | 25,643 | $282073.00 | Dec 15, 2025 |
| CAMPBELL BRADLEY LEWIS | Chief Executive Officer | 14,587 | $146011.00 | Dec 1, 2025 |
| CAMPBELL BRADLEY LEWIS | Chief Executive Officer | 14,587 | $131721.00 | Dec 1, 2025 |
| PROUT SAMANTHA WHITEMAN | Officer | 32,193 | $0.00 | Dec 1, 2025 |
| ROSENBERG ELLEN S | Officer | 95,621 | $514786.00 | Nov 26, 2025 |